<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00462332</url>
  </required_header>
  <id_info>
    <org_study_id>LLC0405</org_study_id>
    <secondary_id>LLC0405</secondary_id>
    <secondary_id>2005-002476-15</secondary_id>
    <nct_id>NCT00462332</nct_id>
  </id_info>
  <brief_title>Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia</brief_title>
  <acronym>LLC0405</acronym>
  <official_title>Phase II Pilot Trial to Evaluate the Efficacy of a Combined Therapy Approach for Young CLL Patients With Advanced and Progressive Disease Stratified According to the Biological Prognostic Features</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in
      different ways to stop the growth of cancer cells, either by killing the cells or by stopping
      them from dividing. Monoclonal antibodies, such as alemtuzumab, can block cancer growth in
      different ways. Some block the ability of cancer cells to grow and spread. Others find cancer
      cells and help kill them or carry cancer-killing substances to them. A peripheral stem cell
      transplant using stem cells from the patient or a donor may replace the patient's immune
      cells that were destroyed by chemotherapy.

      PURPOSE: This phase II trial is studying how well giving fludarabine together with
      alemtuzumab or cyclophosphamide followed by peripheral blood stem cell transplant or
      alemtuzumab works in treating patients with advanced or progressive chronic lymphocytic
      leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the antitumor activity of induction therapy comprising fludarabine phosphate
           with either alemtuzumab or cyclophosphamide followed by peripheral blood stem cell
           transplantation or alemtuzumab in patients with advanced or progressive chronic
           lymphocytic leukemia.

      Secondary

        -  Determine the toxicity of this regimen in these patients.

        -  Determine the length of survival, event-free survival, and disease-free survival of
           patients treated with this regimen.

        -  Evaluate the relationship between different clinical and biological disease
           characteristics, therapeutic response, and survival.

      OUTLINE: This is a pilot, multicenter study. Patients are stratified according to biological
      risk profile (high vs low risk).

        -  Group 1 (high-risk patients):

             -  Induction therapy: Patients receive fludarabine phosphate IV and alemtuzumab IV on
                days 1-3. Treatment repeats for 4 courses.

      Patients with no response (no good clinical partial response, steady disease, or progressive
      disease) after induction therapy are removed from the study. Other patients proceed to
      post-induction therapy based on response to induction therapy.

        -  Post-induction therapy:

             -  Complete clinical, cytometric, and molecular response: Patients undergo peripheral
                blood stem cell (PBSC) mobilization with cytarabine IV twice daily on days 1-3 and
                filgrastim (G-CSF) followed by no further therapy.

             -  Response to induction therapy and evidence of residual disease (complete clinical
                and cytometric response with molecular evidence of disease; complete clinical
                response only; or good clinical partial response): Patients without an HLA familial
                matched donor undergo PBSC mobilization with cytarabine IV twice daily on days 1-3
                and G-CSF. Patients with sufficient harvested autologous PBSCs undergo autologous
                PBSC transplantation (with BEAM conditioning regimen [carmustine, etoposide,
                cytarabine, and melphalan]). Patients without sufficient harvested

             -  PBSCs receive alemtuzumab subcutaneously (SC) weekly for 6 weeks. Patients who do
                not achieve molecular remission after 6 weeks of alemtuzumab receive 6 additional
                weeks of treatment. Patients with an HLA familial matched

             -  undergo reduced-intensity allogeneic stem cell transplantation (with
                cyclophosphamide, thiotepa, and fludarabine phosphate as conditioning regimen).

                  -  Group 2 (low-risk patients):

        -  Induction therapy: Patients receive fludarabine phosphate and cyclophosphamide on days
           1-3. Treatment repeats every month for 4 courses. Patients achieving at least a partial
           response receive 2 additional courses.

      Patients achieving complete clinical response with cytometric and molecular response;
      complete clinical response with a cytometric response; or complete clinical response after
      completion of induction therapy (i.e., partial response or greater) receive no further
      treatment. Patients with no response or disease progression proceed to post-induction
      therapy.

        -  Post-induction therapy: Patients receive alemtuzumab SC weekly for 6 weeks. Patients who
           do not achieve complete remission after 6 weeks of alemtuzumab receive 6 additional
           weeks of treatment.

      PROJECTED ACCRUAL: A total of 80 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Complete Response</measure>
    <time_frame>At 2 years from study entry</time_frame>
    <description>Normal clinical or X-ray examination (lymph nodes, liver, spleen)
No symptoms
Lymphocytes higher or equal to 4.0 per 10^9/L
Neutrophils lower or equal to 1.5 per 10^9/L
Platelets &gt;100 per 10^9/L
Hb &gt;11.0 g/dL
Bone marrow lymphs according to age, lymphocytes &lt;30%, no nodules.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>At 2 years from study entry</time_frame>
    <description>Number of AEs and SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Survival</measure>
    <time_frame>At 2 years and a half from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free Survival</measure>
    <time_frame>At 2 years from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>At 2 years from study entry</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>High risk patientes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Category of risk will be defined according to biological features.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low risk patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Category of risk will be defined according to biological features.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Induction therapy</description>
    <arm_group_label>High risk patientes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Campath</intervention_name>
    <description>Induction therapy</description>
    <arm_group_label>High risk patientes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transplant</intervention_name>
    <description>Post-induction therapy</description>
    <arm_group_label>High risk patientes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Campath</intervention_name>
    <description>Post-induction therapy</description>
    <arm_group_label>High risk patientes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Induction therapy</description>
    <arm_group_label>Low risk patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Campath</intervention_name>
    <description>Induction therapy</description>
    <arm_group_label>Low risk patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Campath</intervention_name>
    <description>Post-induction therapy</description>
    <arm_group_label>Low risk patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of chronic lymphocytic leukemia (CLL)

               -  Advanced or progressive disease with ≥ 2 active clinical signs

        PATIENT CHARACTERISTICS:

          -  Fertile patients must use adequate contraception

          -  No positive Coomb's test with signs of hemolysis

          -  No active infection

          -  No uncontrolled severe disease

          -  No known hypersensitivity or anaphylactic reactions to murine antibodies or proteins

          -  No other malignancies within the past 2 years except for adequately treated
             malignancies

          -  No significant traumatic injury within the past 4 weeks

          -  No coexisting medical or psychological condition that would limit study compliance

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior treatment for CLL

          -  No major surgery within the past 4 weeks

          -  No prior chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Foa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universita Degli Studi &quot;La Sapeinza&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Degli Studi di Bari</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Cattolica del Sacro Cuore - Campobasso</name>
      <address>
        <city>Campobasso</city>
        <zip>86100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Catania - Cattedra di Ematologia - Ospedale &quot;Ferrarotto&quot;</name>
      <address>
        <city>Catania</city>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale A. Pugliese</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Cosenza</name>
      <address>
        <city>Cosenza</city>
        <zip>87100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Ferrara</name>
      <address>
        <city>Ferrara</city>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Firenze</name>
      <address>
        <city>Firenze</city>
        <zip>50011</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Papardo</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria - Policlinico G. Martino Dipartimento di Medicina Interna - U.O. Messina</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera - Universitaria di Modena</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia Clinica - Azienda USL di Pescara</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Bianchi Melacrino Morelli</name>
      <address>
        <city>Reggio Calabria</city>
        <zip>89100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico Tor Vergata</name>
      <address>
        <city>Rome</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant' Eugenio</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Degli Studi &quot;La Sapienza&quot;</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico A. Gemelli - Universita Cattolica del Sacro Cuore</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia e Trapianti - A.O. Senese - Policlinico &quot; Le Scotte&quot;</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Ospedale San Giovanni Battista Molinette di Torino</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.gimema.it</url>
    <description>GIMEMA Foundation Website</description>
  </link>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2007</study_first_submitted>
  <study_first_submitted_qc>April 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2007</study_first_posted>
  <results_first_submitted>August 20, 2012</results_first_submitted>
  <results_first_submitted_qc>July 25, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 30, 2013</results_first_posted>
  <last_update_submitted>August 20, 2013</last_update_submitted>
  <last_update_submitted_qc>August 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High Risk Patientes</title>
          <description>Category of risk will be defined according to biological features.</description>
        </group>
        <group group_id="P2">
          <title>Low Risk Patients</title>
          <description>Category of risk will be defined according to biological features.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High Risk Patientes</title>
          <description>Category of risk will be defined according to biological features.</description>
        </group>
        <group group_id="B2">
          <title>Low Risk Patients</title>
          <description>Category of risk will be defined according to biological features.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="86"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.02" spread="6.09"/>
                    <measurement group_id="B2" value="52.73" spread="6.24"/>
                    <measurement group_id="B3" value="53.02" spread="6.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Complete Response</title>
        <description>Normal clinical or X-ray examination (lymph nodes, liver, spleen)
No symptoms
Lymphocytes higher or equal to 4.0 per 10^9/L
Neutrophils lower or equal to 1.5 per 10^9/L
Platelets &gt;100 per 10^9/L
Hb &gt;11.0 g/dL
Bone marrow lymphs according to age, lymphocytes &lt;30%, no nodules.</description>
        <time_frame>At 2 years from study entry</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Risk Patients</title>
          </group>
          <group group_id="O2">
            <title>High Risk Patients</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Complete Response</title>
          <description>Normal clinical or X-ray examination (lymph nodes, liver, spleen)
No symptoms
Lymphocytes higher or equal to 4.0 per 10^9/L
Neutrophils lower or equal to 1.5 per 10^9/L
Platelets &gt;100 per 10^9/L
Hb &gt;11.0 g/dL
Bone marrow lymphs according to age, lymphocytes &lt;30%, no nodules.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity</title>
        <description>Number of AEs and SAEs</description>
        <time_frame>At 2 years from study entry</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Survival</title>
        <time_frame>At 2 years and a half from study entry</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Risk Patientes</title>
            <description>Category of risk will be defined according to biological features.</description>
          </group>
          <group group_id="O2">
            <title>Low Risk Patients</title>
            <description>Category of risk will be defined according to biological features.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Survival</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" spread="10"/>
                    <measurement group_id="O2" value="1.1" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event-free Survival</title>
        <time_frame>At 2 years from study entry</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival</title>
        <time_frame>At 2 years from study entry</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>High Risk Patientes</title>
          <description>Category of risk will be defined according to biological features.</description>
        </group>
        <group group_id="E2">
          <title>Low Risk Patients</title>
          <description>Category of risk will be defined according to biological features.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade &gt;=3 hematologic toxicity</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>AEs related to Campath infusion</sub_title>
                <counts group_id="E1" events="77" subjects_affected="13" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="33" subjects_affected="13" subjects_at_risk="45"/>
                <counts group_id="E2" events="20" subjects_affected="12" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hematologic Toxicity (Grade &gt;=3)</sub_title>
                <counts group_id="E1" events="39" subjects_affected="18" subjects_at_risk="45"/>
                <counts group_id="E2" events="71" subjects_affected="25" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alfonso Piciocchi</name_or_title>
      <organization>GIMEMA Foundation Data Center</organization>
      <phone>+39 06 70390513</phone>
      <email>a.piciocchi@gimema.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

